** Shares of vaccine maker Novavax NVAX.O fall 6.6% to $6.61 in afternoon trading
** US FDA is asking Novavax to conduct an additional clinical trial for its COVID-19 vaccine, despite previous 90% efficacy results, the Wall Street Journal reports, citing people familiar with the matter
** The request came after appointees under Health Secretary Robert F. Kennedy Jr. intervened in the approval process - WSJ
** Novavax did not immediately respond to a Reuters request for comment
** On Wednesday, NVAX said US FDA asked the company to produce more data on its COVID-19 vaccine if it gets full approval
** Including session's moves, stock down 12.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。